Study ID (Protocol Number)
CA186-011
 
STUDY LOCATIONS*


 




*Not all study site locations may be listed - please check back soon for updated
information. For more information regarding other participating countries, please
visit clinicaltrials.gov.
  STUDY NAME
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
STUDY OVERVIEW
The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma
 

 
The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.
Find A Study